The plant-based food producer boosted its valuation to $4bn and has now raised $1.5bn since being founded by Stanford faculty in 2011.

Thrive Earlier Detection, the developer of an early cancer screening blood test invented at JHU, has raised $257m in series B funding.

Sema4, spun out of Icahn School of Medicine, has achieved a valuation of more than $1bn following a $121m series C round.

Co-founded by faculty from Columbia University and University of Melbourne, Praxis Precision Medicines targets CNS disorders.

Seek Group returned for a series F round that boosted the Stanford faculty-founded adult education provider's valuation to $2.5bn.

GlaxoSmithKline is paying $176m for a 10% stake in University of Tübingen's RNA drug developer in connection with a strategic partnership agreement.

The Zhejiang University Future Capital-backed cancer and inflammatory disease drug developer has now raised more than $260m in under two years.

Columbia University’s Vor Biopharma has collected more capital from shareholders including Osage University Partners, Johnson & Johnson and PureTech Health.

The round pushed the overall funding for Stanford's autoimmune and neurodegenerative disorder drug developer past $250m.

Advancing research from institutions including Harvard, kidney disease-focused Goldfinch Bio now has its sights on clinical trials.